Despite losing patent protection for its blockbuster drug, Singulair, over the summer, pharma giant Merck's (NYSE: MRK) shares have appreciated 18% year to date, and the company has a slew of therapeutics in development. In addition, while some of the biggest players in the health care space -- including Pfizer (NYSE: PFE) and Abbott (NYSE: ABT) -- are spinning-out businesses, Merck doesn't look like it will be following suit.
In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Merck's current strategy and give a helpful overview of the company's main growth drivers.
